MK-677

Ghrelin Receptor Agonism at the Pituitary and Hypothalamus#

MK-677 is a non-peptide, orally active agonist of the growth hormone secretagogue receptor 1a (GHS-R1a) — the same receptor that endogenous ghrelin binds. By activating GHS-R1a in the anterior pituitary and the hypothalamic arcuate nucleus, it amplifies GHRH signaling and suppresses somatostatin tone, driving pulsatile endogenous GH release rather than a flat exogenous spike. This is the critical architectural difference from injecting rHGH: you keep your body's native pulse pattern intact, just at a higher amplitude.

"Once-daily oral administration of MK-677 at 25 mg produced sustained, dose-dependent increases in GH and IGF-I in GH-deficient adults, supporting its utility as a non-injectable secretagogue." — Chapman IM et al. Journal of Clinical Endocrinology & Metabolism, 1997

Sustained IGF-1 Elevation Without Tachyphylaxis#

Elevated GH pulses drive hepatic IGF-1 production, and because IGF-1 has a ~15-hour half-life, a single daily MK-677 dose keeps serum IGF-1 elevated across the full 24-hour cycle. Most users see IGF-1 climb 40–80% above baseline on bloods within 6–8 weeks. Critically, the axis does not desensitize — elderly subjects ran 25 mg daily for two full years with sustained IGF-1 in the young-adult range. This is what makes MK-677 viable for long runs where an injectable GHRP stack would demand cycling and dose rotation.

"Daily administration of the oral ghrelin mimetic MK-677 significantly increased fat-free mass and serum IGF-1 concentrations into the young-adult range, with no evidence of waning effect over 2 years." — Nass R et al. Annals of Internal Medicine, 2008

The practical outcome: slow, steady accrual of fat-free mass, improved nitrogen retention, and the connective-tissue, skin, and recovery benefits of a chronically elevated GH/IGF-1 axis.

Slow-Wave Sleep and Recovery#

GHS-R1a activation enhances stage 3/4 slow-wave sleep (SWS) — the deep, GH-pulsing phase where most physical recovery happens. This is why bedtime dosing is the community default: you're stacking the pharmacologically-induced GH pulse onto the natural nocturnal pulse, inside deeper sleep architecture. Users consistently report more vivid dreams, longer uninterrupted sleep, and noticeably better next-day recovery. For the lifter this translates to faster between-session turnaround; for the looksmaxxer and longevity crowd, it's arguably the single most valuable effect on the compound.

Appetite Stimulation via the Ghrelin Pathway#

Because MK-677 mimics ghrelin, it reliably triggers the same orexigenic signaling — increased hunger, faster gastric emptying, stronger food-reward response. For hardgainers and offseason bulks this is a feature: eating the surplus stops being a chore. For anyone cutting aggressively, it's a liability — plan around it or drop the dose.

Transient Cortisol and Prolactin Rise#

Early doses produce a modest bump in cortisol and prolactin that normalizes by roughly week two of continuous use. This is a class effect of ghrelin-mimetic signaling, not a sign of HPA dysregulation, and it does not require ancillaries.

"MK-677 increased daytime mean serum GH concentrations, IGF-I, and fat-free mass with a transient rise in cortisol and prolactin that normalized by week 2." — Svensson J et al. Journal of Clinical Endocrinology & Metabolism, 1998

Downstream Effects on Bone, Connective Tissue, and Glucose#

Sustained IGF-1 elevation drives measurable increases in bone formation markers (P1NP, osteocalcin, IGFBP-5) alongside resorption markers, consistent with accelerated bone remodeling. The same IGF-1 signal supports tendon and ligament collagen turnover, which is why MK-677 pairs well with BPC-157 in soft-tissue rehab stacks.

"Eight weeks of MK-677 treatment significantly increased markers of both bone formation (P1NP, osteocalcin, IGFBP-5) and bone resorption in healthy subjects." — Svensson J et al. Journal of Bone and Mineral Research, 1998

The tradeoff sits on the glucose side. Chronically elevated GH antagonizes insulin action at the receptor level, producing reduced insulin sensitivity and mild fasting hyperglycemia over time. This is the single real long-term management item on MK-677 — not estrogen, not HPTA, not liver. Track fasting glucose and HbA1c quarterly, and be honest about pulling back if HbA1c drifts past 5.7%.

Common (most users)#

• Ravenous appetite — the defining MK-677 side effect, usually peaks in weeks 1–3 and attenuates but rarely disappears entirely. Feature on a bulk, bug on a cut. Mitigate by front-loading protein and fiber at each meal, dosing at bedtime (so peak hunger hits while you're asleep), and planning high-volume low-calorie meals if you're trying to stay lean.
• Water retention / puffy face, hands, ankles — classic GH-axis signature. Usually settles within 4–6 weeks as the axis recalibrates. Keep sodium reasonable, don't simultaneously run a wet AAS like dbol or high-dose test, and stay well-hydrated (paradoxically this reduces the retention, not worsens it).
• Lethargy / morning grogginess — more common at 25 mg than 12.5 mg, and more common with AM dosing. Shift to bedtime and it usually resolves within a week.
• Vivid, cinematic dreams — from enhanced slow-wave sleep. Benign and usually enjoyable. No action needed.
• Mild numbness or tingling in hands (paresthesia) — dose-dependent GH-axis effect. If it becomes uncomfortable or wakes you up, drop from 25 → 12.5 mg and it typically resolves in 1–2 weeks.

"MK-677 increased daytime mean serum GH concentrations, IGF-I, and fat-free mass with a transient rise in cortisol and prolactin that normalized by week 2." — Svensson et al., JCEM (1998)

Uncommon (dose-dependent or individual)#

• Elevated fasting glucose and reduced insulin sensitivity — the single most important thing to monitor. Mean fasting glucose rose ~5 mg/dL in the 2-year trial, with a measurable drop in insulin sensitivity. Check fasting glucose, fasting insulin, and HbA1c at baseline, week 8, and every 3 months on-cycle. If HbA1c drifts past 5.7% or fasting glucose past 100 mg/dL on consecutive draws, drop to 12.5 mg or come off.
• Transient cortisol and prolactin bump in the first 1–2 weeks. Rarely symptomatic but can cause some initial moodiness or water retention that self-resolves. No cabergoline or ancillary needed.
• Mild carpal-tunnel-like symptoms (wrist pain, hand stiffness on waking) at 25 mg+ in susceptible users. Drop the dose. This is GH/IGF-1-driven, not nerve damage, and reverses cleanly.
• Lower-extremity edema beyond 6 weeks — if the ankle/shin puffiness isn't settling, you're likely getting more IGF-1 exposure than you need. 12.5 mg maintains most of the benefit with dramatically less fluid retention.
• Snoring / worsened sleep-disordered breathing — GH-axis elevation thickens soft-tissue airway. If your partner says your snoring got worse or you're waking up unrefreshed, get a sleep study before continuing.
• Mild blood pressure creep from fluid retention. Cuff weekly; if systolic trends past 135 and it's clearly the MK-677 (not a stacked AAS), dose-reduce.

"Daily administration of the oral ghrelin mimetic MK-677 significantly increased fat-free mass and serum IGF-1 concentrations into the young-adult range, with no evidence of waning effect over 2 years." — Nass et al., Annals of Internal Medicine (2008)

Rare but serious#

• New-onset type 2 diabetes — documented in predisposed users, particularly when MK-677 is stacked with SARMs or AAS. Warning signs: polyuria, polydipsia, unexplained fatigue, rapid visual changes, HbA1c jumping from normal into the 6.0+ range between draws. Stop immediately and get a full metabolic panel.
• Clinically significant fluid overload in users with undiagnosed cardiac dysfunction — rapid weight gain (several pounds in a week that isn't food), shortness of breath on stairs, orthopnea. Stop and get evaluated. The healthy bodybuilding population rarely sees this, but it's the reason CHF trials of GH secretagogues were halted.
• Unmasking of occult malignancy growth — elevated IGF-1 is mitogenic. Long-term use in someone with an undiagnosed hormone-responsive tumor is a theoretical risk that has not been well quantified in human trials, but it's the rationale behind the active-malignancy contraindication.

"MK-677 intake is associated with an increase in insulin resistance and development of overt diabetes, particularly when combined with androgens or in predisposed individuals." — Sotorník et al., Clinical Diabetes (2022)

Hard contraindications#

• Type 2 diabetes or prediabetes — MK-677 will worsen glycemic control. Don't run it.
• Active malignancy, especially hormone-responsive or IGF-1-sensitive tumors (breast, prostate, colorectal) — elevated IGF-1 is mitogenic. Hard no.
• Congestive heart failure or significant ventricular dysfunction — fluid retention can decompensate a failing heart.
• Untreated moderate-to-severe sleep apnea — GH-axis elevation worsens airway collapse. Get the apnea treated first, then reassess.
• Pregnancy — no safety data, and the IGF-1 elevation is not something to introduce to a developing fetus.
• Stacking with high-dose insulin without glucose monitoring discipline — MK-677 blunts insulin sensitivity. Running slin on top without checking BG frequently is how people wreck their pancreas.

Gender, PCT, and population notes#

Women tolerate MK-677 well at 10–15 mg/day. It's non-hormonal and non-virilizing — no voice changes, no clitoral hypertrophy, no cycle disruption. The practical limiter for lean-chasing females is the appetite stimulation, which can derail a cut.

No PCT is required. MK-677 does not suppress HPTA, LH, FSH, or endogenous testosterone. It's actually one of the better adjuncts to run through PCT from an AAS cycle — the elevated IGF-1 helps hold gains during the low-androgen window when cortisol is climbing and you're most vulnerable to muscle loss.

Older users (40+) often get the best subjective response (skin, sleep, body composition) because baseline GH/IGF-1 is lower and there's more room to restore. They're also the cohort most likely to have borderline glycemic markers — bloodwork discipline matters more here, not less.